RPA

Opportunity: Use RPA to Help You Save Money

Are some of your business processes inefficient but too complicated to exhaustively reengineer right now? Don’t overlook the ways RPA can automate small and large-scale business processes in most industries and departments. Check out where to start, what actions to take, how to organize your teams, and what to avoid.

READ MORE
AI

Hiring data says “most firms not building AI-development teams”

With few exceptions, when it comes to significant, strategic AI investments, enterprises are waiting for the “IT bigs” to do it for them by enhancing their portfolios with new, AI-based capabilities. Job posting data speaks volumes. Listen to the data.

READ MORE
IBM

IBM Battles at the Edge of the Market

A centuries-old military aphorism claims that “all battles occur at the edges where two maps meet.” The implication is that the most critical aspect of combat takes place where details are lacking, and control is limited at best. IBM gets this, and it is the reason behind their critical edge computing announcements at last week’s…

READ MORE
OT

It’s Time to Demystify OT, What a CxO Needs to Know

In my first Analyst Syndicate post, I talked about the ongoing IT-OT civil war and why a CIO or other tech-related CxO needs to actively address the issue to get the most from Digital Transformation. The questions that blog raises has prompted this blog post about what the roots of the tribalism Prediction 2020 revealed…

READ MORE
AI

Stop confusing AI with Intelligence

AI researchers don’t think of intelligence the same way other people do. On hearing that “an AI” can play GO better than human champions, ordinary people assume that those skills can generalize. After all, that’s what people do. AI has no generalized smarts.

READ MORE
AI

An Update on IBM Watson for Health Care — Ignore The AI Carnival Barkers

Reading time: 2 minutes 30 seconds Check the news on IBM Watson for Health Care: STAT reports that IBM is halting sales of Watson AI for drug discovery FierceBiotch reports that IBM employees were recently told of this decision and are reassessing Watson’s prospects in the broader biopharma industry. Troubles in IBM’s Watson for Oncology…

READ MORE